Page 151 - MI-2-4

Microbes & Immunity Glioblastoma therapy: Immunotherapy and inhibitors

tumor cells. J Cell Physiol. 2015;230(1):131-139. 97. Sminia P, Westerman BA. Blood-brain barrier crossing and
breakthroughs in glioblastoma therapy. Br J Clin Pharmacol.
doi: 10.1002/jcp.24689
2016;81(6):1018-1020.
95. Haynik DM, Roma AA, Prayson RA. HER-2/neu expression
in glioblastoma multiforme. Appl Immunohistochem Mol doi: 10.1111/bcp.12881
Morphol. 2007;15(1):56-58. 98. Łazewska D, Wiecek M, Ligneau X, et al. Histamine H 3
and H receptor affinity of branched 3-(1H-imidazol-
doi: 10.1097/01.pai.0000213133.09160.da 4
4-yl)propyl N-alkylcarbamates. Bioorg Med Chem Lett.
96. Lankheet NA, Hillebrand MJ, Rosing H, Schellens JH, 2009;19(23):6682-6685.
Beijnen JH, Huitema AD. Method development and
validation for the quantification of dasatinib, erlotinib, doi: 10.1016/j.bmcl.2009.10.005
gefitinib, imatinib, lapatinib, nilotinib, sorafenib and 99. Wang D, Wang C, Wang L, Chen Y. A comprehensive review
sunitinib in human plasma by liquid chromatography in improving delivery of small-molecule chemotherapeutic
coupled with tandem mass spectrometry. Biomed agents overcoming the blood-brain/brain tumor barriers for
Chromatogr. 2013;27(4):466-476. glioblastoma treatment. Drug Deliv. 2019;26(1):551-565.
doi: 10.1002/bmc.2814 doi: 10.1080/10717544.2019.1616235

Volume 2 Issue 4 (2025) 143 doi: 10.36922/mi.5075